Non-Hodgkin Lymphoma Clinical Trials

Non-Hodgkin lymphoma clinical trials give patients opportunities to access the latest treatments before those options are available in other settings. For instance, novel immunotherapies and chemotherapy medications are first evaluated in clinical trials before being used in traditional settings. Trial participants must adhere to strict protocols in carefully controlled conditions so that researchers can study the drug’s effectiveness, safety and possible side effects to determine whether the drug is safe and effective for patients. As a result, non-Hodgkin lymphoma patients are among some of the first to benefit from new treatments for their condition.

Moffitt Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, conducts hundreds of clinical trials each year, some of which focus on non-Hodgkin lymphoma diagnosis and treatment options. Recent trials have centered on:

  • New strategies for improving response rates to stem cell transplantation
  • Novel maintenance therapies for use after initial non-Hodgkin lymphoma treatment
  • Tumor-suppressing immunotherapies and biologic treatments

With a skilled research faculty and support team, as well as designated programs focusing on chemical biology and molecular medicine, immunology, cancer biology, health outcomes and cancer epidemiology, Moffitt is committed to staying at the forefront of scientific advances for lymphoma diagnosis and treatment. And, by taking a bench-to-bedside approach, we apply what we learn in the lab to our day-to-day patient care, fast-tracking laboratory successes into new treatments for our patients and others across the nation.

How to Enroll in a Clinical Trial at Moffitt

Moffitt Cancer Center can help patients explore their options for accessing the latest advances in non-Hodgkin lymphoma treatment. To learn more about our clinical trials for non-Hodgkin lymphoma,  call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Participation does not require a physician’s referral.

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 19627

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Disease Site: Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19715

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19829

A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20069

A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20571

Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20578

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Disease Site: Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20608

A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Disease Site: Chronic Leukemia (CLL, CML), Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20737

Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release

Disease Site: Hodgkin's Lymphoma, Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20751

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21094

An Open Label, Multi-Cohort, Multi-Center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination with Chemotherapy in Patients with Advanced T-cell Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21096

A Phase I Study of Duvelisib in Combination with CC-486 in Lymphoid Malignancy

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21122

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21623

A Phase 1/2 Study of bbT369, a Dual Targeting CAR T cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B cell Non-Hodgkin s Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20397

A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details